Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 20;11(2):e41776.
doi: 10.1016/j.heliyon.2025.e41776. eCollection 2025 Jan 30.

Report of joint hypermobility in malignant hyperthermia susceptible patients: Observational study with a case-control descriptive design

Rita Ccs Santos  1 , Larissa Fcdms Lima  1 , Pâmela V Andrade  1 , Joilson M Santos  1 , Leonardo Galleni  2 , Antonio Fr Junior  2 , Lucas S Souza  2 , Beny Schmidt  3 , Acary Sb Oliveira  4 , José Lg Amaral  1 , Mariz Vainzof  2 , Helga Ca Silva  1
Affiliations

Report of joint hypermobility in malignant hyperthermia susceptible patients: Observational study with a case-control descriptive design

Rita Ccs Santos et al. Heliyon. .

Abstract

Background: Hypermobility is the capacity to perform joint movements in amplitudes greater than normal. Hypermobility is present in nearly 100 % of congenital myopathy central core disease (CCD) patients but is sporadically described in the allelic disease malignant hyperthermia (MH). Our objective was to investigate the frequency/characteristics of hypermobility in MH susceptible patients as compared to a control group, aiming the identification of correlations between hypermobility and demographic/clinical findings in MH patients.

Methods: We recruited 26 MH patients (MH history, positive in vitro contracture test (IVCT), no muscle weakness, no cores in muscle biopsy) and 23 controls (no MH/myopathy history). Patients/medical records were evaluated for obtaining demographic/clinical data. Hypermobility was assessed in all patients and controls with Bulbena score. Goniometry was performed in a subset of 11 patients and 11 controls.

Results: Bulbena score indicative of hypermobility was significantly more frequent in MH than in the control group (50 % versus 13 %, relative risk 2.06 (95%CI 1.27-3.35), chi-square test, p < .01). Goniometric assessment revealed significantly greater range of motion of mostly proximal movements in MH versus control groups. In the MH group, there was no correlation of the Bulbena score with age, sex, clinical complaints of myalgia/cramps, CK levels, IVCT result, or degree of contracture after caffeine or halothane.

Conclusions: It is possible that predominantly proximal hypermobility is part of a clinical spectrum associated with RYR1 gene variants, as it was present even when associated muscle weakness was not present. More studies are necessary to measure evolution and long-term impact of hypermobility in MH patients.

Keywords: Central core disease; Goniometry; Joint instability; Malignant hyperthermia; Myopathy; Ryanodine receptor gene.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Donkervoort S., Bonnemann C.G., Loeys B., Jungbluth H., Voermans N.C. The neuromuscular differential diagnosis of joint hypermobility. Am J Med Genet C Semin Med Genet. 2015;169C(1):23–42. doi: 10.1002/ajmg.c.31433. - DOI - PubMed
    1. Rosenberg H., Sambuughin N., Riazi S., Dirksen R. In: GeneReviews® [Internet] Adam M.P., Ardinger H.H., Pagon R.A., et al., editors. University of Washington, Seattle; Seattle (WA): 1993-2020. Malignant hyperthermia susceptibility. 2020.https://www.ncbi.nlm.nih.gov/books/NBK1146/ Available from: - PubMed
    1. Shuaib A., Paasuke R.T., Brownell K.W. Central core disease. Clinical features in 13 patients. Medicine (Baltim.) 1987;66:389–396. - PubMed
    1. Li G., Brady J.E., Rosemberg H., Sun L.S. Excess comorbities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records. Paediatr Anesth. 2011;21:958–963. doi: 10.1111/j.1460-9592.2011.03649.x. - DOI - PubMed
    1. Knuiman G.J., Küsters B., Eshuis L., Snoeck M., Lammens M., Heytens l, et al. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations. J. Neurol. 2019;266(4):876–887. doi: 10.1007/s00415-019-09209-z. - DOI - PMC - PubMed

LinkOut - more resources